ZoomLenz
Where the heck HHS Secy Becerra been while vaccine makers have left the US market and found standard marketing authorizations overseas, that they didn't get here?
our float is 229,164,012 shares, which is 192.45% of our 119,080,135 issued share total...
Now I'm thinking that our ultimate objective is to close out the unreported Failures to Deliver (FTD's). Do we really want to issue additional shares for that purpose? Or do we just want paid to close out those open positions?
I still think a piece of PCI Pharma remains an objective for the company
Granted, the share price will be reduced by 5, but the issue will become just finding the increased number of shares to deliver. It's going to be impossible to deliver 550M shares, when our new OS is only going to be 595M shares, and 238M of those will likely be restricted and transferred to our business partner.
I think that the supportive data that can be harvested from the ACTIV-5 final report, coupled with the CMML study findings, and including our possibly comparable results to Gohibic in treating stage 6 patients (ACTIV-5 treated stage 5 AND 6 patients), that the FDA may find enough safety and efficacy data to make a favorable decision on approving a resubmitted EUA application...But that will trash Pfizer's tens of billions of annual revenue dollars...That would destroy the case of the mRNA proponents,
especially after Black Horse's investment in Baudax Bio, I have never been more excited and confident in our immediate and spectacular turn-around
So I hope that our intended partner in our business combination is PCI Pharma, and that we can conclude negotiations, and perhaps end up with an equity stake in a company that could become our product manufacturer, and more.
I wonder if TeraImmune was the privately owned biotech that Humanigen was interested in.
Rule 204 Close-out Requirement. Baudax shares?
Janssen is planning on 3-3.5M vaccines, and Novavax recently got an order for additional 1.5M vaccines. If 10-25% of those vaccines are administered with a lenz cocktail, we could be looking at 500K - 1.25M doses of lenz
We probably just checked-off another requirement of the Nasdaq Appeals Panel.
So, we have management telling us in the 10-K that, if a secondary strategic transaction is required, as it may have been, that we needed to move on that by June 30th...June 30th is when Baudax Bio finalized their acquisition of TeraImmune...June 30th is also when Black Horse acquired 500K shares of Baudax Bio. See the 13-G.
(Baudax investment) portends regulatory approval of lenz as a CMML treatment, and will permit a successful 5:1 forward stock split
re-infections reflect a severe deficiency in memory retention on how to fight the virus with mRNA technology. Even more, this approach just causes the virus to continue to mutate.
